The aim of this study was to describe the clinical and molecular genetic findings in seven individuals from three unrelated families with Blau syndrome. A complex ophthalmic and general health examination including diagnostic imaging was performed. The NOD2 mutational hot spot located in exon 4 was Sanger sequenced in all three probands. Two individuals also underwent autoinflammatory disorder gene panel screening, and in one subject, exome sequencing was performed. Blau syndrome presenting as uveitis, skin rush or arthritis was diagnosed in four cases from three families. In two individuals from one family, only camptodactyly was noted, while another member had camptodactyly in combination with non-active uveitis and angioid streaks. One proband developed two attacks of meningoencephalitis attributed to presumed neurosarcoidosis, which is a rare finding in Blau syndrome. The probands from families 1 and 2 carried pathogenic variants in NOD2 (NM_022162.3): c.1001G>A p.(Arg334Gln) and c.1000C>T p.(Arg334Trp), respectively. In family 3, two variants of unknown significance in a heterozygous state were found: c.1412G>T p.(Arg471Leu) in NOD2 and c.928C>T p.(Arg310*) in NLRC4 (NM_001199139.1). In conclusion, Blau syndrome is a phenotypically highly variable, and there is a need to raise awareness about all clinical manifestations, including neurosarcoidosis. Variants of unknown significance pose a significant challenge regarding their contribution to etiopathogenesis of autoinflammatory diseases.

Department of Ophthalmology 1st Faculty of Medicine Charles University and General University Hospital Prague U Nemocnice 2 128 08 Prague Czech Republic

Department of Paediatrics and Inherited Metabolic Disorders 1st Faculty of Medicine Charles University and General University Hospital Prague Ke Karlovu 2 128 08 Prague Czech Republic

Department of Radiology 1st Faculty of Medicine Charles University and General University Hospital Prague Katerinska 30 128 21 Prague Czech Republic

See more in PubMed

Karacan I., Balamir A., Ugurlu S., Aydin A.K., Everest E., Zor S., Onen M.O., Dasdemir S., Ozkaya O., Sozeri B., et al. Diagnostic utility of a targeted next-generation sequencing gene panel in the clinical suspicion of systemic autoinflammatory diseases: A multi-center study. Rheumatol. Int. 2019;39:911–919. doi: 10.1007/s00296-019-04252-5. PubMed DOI

Krainer J., Siebenhandl S., Weinhausel A. Systemic autoinflammatory diseases. J. Autoimmun. 2020;109:102421. doi: 10.1016/j.jaut.2020.102421. PubMed DOI PMC

Martin A.R., Williams E., Foulger R.E., Leigh S., Daugherty L.C., Niblock O., Leong I.U.S., Smith K.R., Gerasimenko O., Haraldsdottir E., et al. PanelApp crowdsources expert knowledge to establish consensus diagnostic gene panels. Nat. Genet. 2019;51:1560–1565. doi: 10.1038/s41588-019-0528-2. PubMed DOI

Blau E.B. Familial granulomatous arthritis, iritis, and rash. J. Pediatr. 1985;107:689–693. doi: 10.1016/s0022-3476(85)80394-2. PubMed DOI

Zhong Z., Ding J., Su G., Liao W., Gao Y., Zhu Y., Deng Y., Li F., Du L., Gao Y., et al. Genetic and Clinical Features of Blau Syndrome among Chinese Patients with Uveitis. Ophthalmology. 2022;129:821–828. doi: 10.1016/j.ophtha.2022.03.014. PubMed DOI

Rose C.D., Wouters C.H., Meiorin S., Doyle T.M., Davey M.P., Rosenbaum J.T., Martin T.M. Pediatric granulomatous arthritis: An international registry. Arthritis Rheum. 2006;54:3337–3344. doi: 10.1002/art.22122. PubMed DOI

Arostegui J.I., Arnal C., Merino R., Modesto C., Antonia Carballo M., Moreno P., Garcia-Consuegra J., Naranjo A., Ramos E., de Paz P., et al. NOD2 gene-associated pediatric granulomatous arthritis: Clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007;56:3805–3813. doi: 10.1002/art.22966. PubMed DOI

Rose C.D., Pans S., Casteels I., Anton J., Bader-Meunier B., Brissaud P., Cimaz R., Espada G., Fernandez-Martin J., Hachulla E., et al. Blau syndrome: Cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. Rheumatology. 2015;54:1008–1016. doi: 10.1093/rheumatology/keu437. PubMed DOI

Poline J., Bourrat E., Meinzer U. Camptodactlyly in Pediatric Practice: Blau Syndrome. J. Pediatr. 2020;221:257–259. doi: 10.1016/j.jpeds.2020.01.057. PubMed DOI

Hurley C.M., McHugh N., Carr S., Kelly J.L. Camptodactyly and DiGeorge syndrome: A rare hand anomaly. JPRAS Open. 2021;28:126–130. doi: 10.1016/j.jpra.2021.03.001. PubMed DOI PMC

Masel G., Halbert A. Blau syndrome presenting with ichthyosis. Australas. J. Dermatol. 2005;46:29–32. doi: 10.1111/j.1440-0960.2005.00134.x. PubMed DOI

Okafuji I., Nishikomori R., Kanazawa N., Kambe N., Fujisawa A., Yamazaki S., Saito M., Yoshioka T., Kawai T., Sakai H., et al. Role of the NOD2 genotype in the clinical phenotype of Blau syndrome and early-onset sarcoidosis. Arthritis Rheum. 2009;60:242–250. doi: 10.1002/art.24134. PubMed DOI

Wang X., Kuivaniemi H., Bonavita G., Mutkus L., Mau U., Blau E., Inohara N., Nunez G., Tromp G., Williams C.J. CARD15 mutations in familial granulomatosis syndromes: A study of the original Blau syndrome kindred and other families with large-vessel arteritis and cranial neuropathy. Arthritis Rheum. 2002;46:3041–3045. doi: 10.1002/art.10618. PubMed DOI

Carreno E., Guly C.M., Chilov M., Hinchcliffe A., Arostegui J.I., Lee R.W., Dick A.D., Ramanan A.V. Optic nerve and retinal features in uveitis associated with juvenile systemic granulomatous disease (Blau syndrome) Acta Ophthalmol. 2015;93:253–257. doi: 10.1111/aos.12544. PubMed DOI

Simonini G., Xu Z., Caputo R., De Libero C., Pagnini I., Pascual V., Cimaz R. Clinical and transcriptional response to the long-acting interleukin-1 blocker canakinumab in Blau syndrome-related uveitis. Arthritis Rheum. 2013;65:513–518. doi: 10.1002/art.37776. PubMed DOI PMC

Sarens I.L., Casteels I., Anton J., Bader-Meunier B., Brissaud P., Chedeville G., Cimaz R., Dick A.D., Espada G., Fernandez-Martin J., et al. Blau Syndrome-Associated Uveitis: Preliminary Results from an International Prospective Interventional Case Series. Am. J. Ophthalmol. 2018;187:158–166. doi: 10.1016/j.ajo.2017.08.017. PubMed DOI

Matsuda T., Kambe N., Ueki Y., Kanazawa N., Izawa K., Honda Y., Kawakami A., Takei S., Tonomura K., Inoue M., et al. Clinical characteristics and treatment of 50 cases of Blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation. Ann. Rheum. Dis. 2020;79:1492–1499. doi: 10.1136/annrheumdis-2020-217320. PubMed DOI

Wouters C.H., Maes A., Foley K.P., Bertin J., Rose C.D. Blau syndrome, the prototypic auto-inflammatory granulomatous disease. Pediatr. Rheumatol. Online J. 2014;12:33. doi: 10.1186/1546-0096-12-33. PubMed DOI PMC

Deguchi A., Mano T., Iwasa N., Ozaki M., Nakase K., Kanazawa N., Sugie K. [A case of hydrocephalus during the course of sporadic Blau syndrome] Rinsho Shinkeigaku. 2021;61:692–695. doi: 10.5692/clinicalneurol.cn-001600. PubMed DOI

Emaminia A., Nabavi M., Mousavi Nasab M., Kashef S. Central nervous system involvement in Blau syndrome: A new feature of the syndrome? J. Rheumatol. 2007;34:2504–2505. PubMed

Jabs D.A., Houk J.L., Bias W.B., Arnett F.C. Familial granulomatous synovitis, uveitis, and cranial neuropathies. Am. J. Med. 1985;78:801–804. doi: 10.1016/0002-9343(85)90286-4. PubMed DOI

Stern B.J., Royal W., 3rd, Gelfand J.M., Clifford D.B., Tavee J., Pawate S., Berger J.R., Aksamit A.J., Krumholz A., Pardo C.A., et al. Definition and Consensus Diagnostic Criteria for Neurosarcoidosis: From the Neurosarcoidosis Consortium Consensus Group. JAMA Neurol. 2018;75:1546–1553. doi: 10.1001/jamaneurol.2018.2295. PubMed DOI

Bradshaw M.J., Pawate S., Koth L.L., Cho T.A., Gelfand J.M. Neurosarcoidosis: Pathophysiology, Diagnosis, and Treatment. Neurol. Neuroimmunol. Neuroinflamm. 2021;8:e1084. doi: 10.1212/NXI.0000000000001084. PubMed DOI PMC

Hoyle J.C., Jablonski C., Newton H.B. Neurosarcoidosis: Clinical review of a disorder with challenging inpatient presentations and diagnostic considerations. Neurohospitalist. 2014;4:94–101. doi: 10.1177/1941874413519447. PubMed DOI PMC

Miceli-Richard C., Lesage S., Rybojad M., Prieur A.M., Manouvrier-Hanu S., Hafner R., Chamaillard M., Zouali H., Thomas G., Hugot J.P. CARD15 mutations in Blau syndrome. Nat. Genet. 2001;29:19–20. doi: 10.1038/ng720. PubMed DOI

Germain D.P. Pseudoxanthoma elasticum. Orphanet J. Rare Dis. 2017;12:85. doi: 10.1186/s13023-017-0639-8. PubMed DOI PMC

Bergen A.A., Plomp A.S., Schuurman E.J., Terry S., Breuning M., Dauwerse H., Swart J., Kool M., van Soest S., Baas F., et al. Mutations in ABCC6 cause pseudoxanthoma elasticum. Nat. Genet. 2000;25:228–231. doi: 10.1038/76109. PubMed DOI

van Duist M.M., Albrecht M., Podswiadek M., Giachino D., Lengauer T., Punzi L., De Marchi M. A new CARD15 mutation in Blau syndrome. Eur. J. Hum. Genet. 2005;13:742–747. doi: 10.1038/sj.ejhg.5201404. PubMed DOI

Yaron Y., Ofen Glassner V., Mory A., Zunz Henig N., Kurolap A., Bar Shira A., Brabbing Goldstein D., Marom D., Ben Sira L., Baris Feldman H., et al. Exome sequencing as first-tier test for fetuses with severe central nervous system structural anomalies. Ultrasound Obstet. Gynecol. 2022;60:59–67. doi: 10.1002/uog.24885. PubMed DOI PMC

Karczewski K.J., Francioli L.C., Tiao G., Cummings B.B., Alfoldi J., Wang Q., Collins R.L., Laricchia K.M., Ganna A., Birnbaum D.P., et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020;581:434–443. doi: 10.1038/s41586-020-2308-7. PubMed DOI PMC

Richards S., Aziz N., Bale S., Bick D., Das S., Gastier-Foster J., Grody W.W., Hegde M., Lyon E., Spector E., et al. Standards and guidelines for the interpretation of sequence variants: A joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med. 2015;17:405–424. doi: 10.1038/gim.2015.30. PubMed DOI PMC

Bennett D., Cameli P., Lanzarone N., Carobene L., Bianchi N., Fui A., Rizzi L., Bergantini L., Cillis G., d’Alessandro M., et al. Chitotriosidase: A biomarker of activity and severity in patients with sarcoidosis. Respir. Res. 2020;21:6. doi: 10.1186/s12931-019-1263-z. PubMed DOI PMC

Bergantini L., Bianchi F., Cameli P., Mazzei M.A., Fui A., Sestini P., Rottoli P., Bargagli E. Prognostic Biomarkers of Sarcoidosis: A Comparative Study of Serum Chitotriosidase, ACE, Lysozyme, and KL-6. Dis. Markers. 2019;2019:8565423. doi: 10.1155/2019/8565423. PubMed DOI PMC

Bazewicz M., Heissigerova J., Pavesio C., Willermain F., Skrzypecki J. Ocular sarcoidosis in adults and children: Update on clinical manifestation and diagnosis. J. Ophthalmic Inflamm. Infect. 2023;13:41. doi: 10.1186/s12348-023-00364-z. PubMed DOI PMC

Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E., Fennell T., O’Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B., et al. Analysis of protein-coding genetic variation in 60,706 humans. Nature. 2016;536:285–291. doi: 10.1038/nature19057. PubMed DOI PMC

Miksch S., Lumsden A., Guenther U.P., Foernzler D., Christen-Zach S., Daugherty C., Ramesar R.K., Lebwohl M., Hohl D., Neldner K.H., et al. Molecular genetics of pseudoxanthoma elasticum: Type and frequency of mutations in ABCC6. Hum. Mutat. 2005;26:235–248. doi: 10.1002/humu.20206. PubMed DOI

Mao L., Dhar A., Meng G., Fuss I., Montgomery-Recht K., Yang Z., Xu Q., Kitani A., Strober W. Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function. Front. Immunol. 2022;13:988862. doi: 10.3389/fimmu.2022.988862. PubMed DOI PMC

Kumrah R., Pilania R.K., Menia N.K., Rawat A., Sharma J., Gupta A., Vignesh P., Jindal A.K., Rikhi R., Agarwal A., et al. Blau syndrome: Lessons learned in a tertiary care centre at Chandigarh, North India. Front. Immunol. 2022;13:932919. doi: 10.3389/fimmu.2022.932919. PubMed DOI PMC

Nordlander S., Pott J., Maloy K.J. NLRC4 expression in intestinal epithelial cells mediates protection against an enteric pathogen. Mucosal Immunol. 2014;7:775–785. doi: 10.1038/mi.2013.95. PubMed DOI PMC

Bardet J., Laverdure N., Fusaro M., Picard C., Garnier L., Viel S., Collardeau-Frachon S., Guillebon J.M., Durieu I., Casari-Thery C., et al. NLRC4 GOF Mutations, a Challenging Diagnosis from Neonatal Age to Adulthood. J. Clin. Med. 2021;10:4369. doi: 10.3390/jcm10194369. PubMed DOI PMC

Kisla Ekinci R.M., Balci S., Dogan H., Ceylaner S., Varan C., Erdem S., Coban F., Bisgin A. Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome Resembling Juvenile Idiopathic Arthritis: A Single-Center Experience from Southern Turkey. Mol. Syndr. 2021;12:112–117. doi: 10.1159/000513111. PubMed DOI PMC

Young M., Goldman-Yassen A., Anderson M., Thakral A., Dutt M., Wolf D., Morris M., Gombolay G. Neurosarcoidosis in children: A systematic review and summary of cases, imaging and management. J. Neuroimmunol. 2022;371:577938. doi: 10.1016/j.jneuroim.2022.577938. PubMed DOI PMC

Thacker N.M., Demer J.L. Chorioretinitis as a complication of pauciarticular juvenile rheumatoid arthritis. J. Pediatr. Ophthalmol. Strabismus. 2005;42:183–184. doi: 10.3928/01913913-20050501-08. PubMed DOI

Petrescu L., Crisan M., Lazar C., Stan C. Anterior and posterior uveitis associated with juvenile idiopathic arthritis -case report. Rom. J. Ophthalmol. 2022;66:185–190. doi: 10.22336/rjo.2022.36. PubMed DOI PMC